Crowell & Moring Represents Halda Therapeutics in Landmark Alliance With VantAI To Discover Next-Generation RIPTAC Medicines

New York – August 19, 2025: Crowell & Moring represented Halda Therapeutics in a strategic research collaboration, worth over $1 billion in total potential value, with VantAI to discover next-generation RIPTAC (Regulated Induced Proximity Targeting Chimeras) medicines.

This landmark alliance aims to accelerate the discovery and development of selective proximity-based therapies across cancer and immunology indications. The agreement includes upfront payments, research support, success-based development and commercial milestones, and tiered royalties on net sales, with a path to expand the collaboration over time.

Under the partnership, VantAI will leverage its Neo-1 foundation model and NeoLink high-throughput structural proteomics platform to rapidly identify and validate novel, context-specific target-effector pairs. These pairs—across both oncology and immunology—will feed directly into Halda’s proprietary RIPTAC development pipeline, which harnesses a distinctive “hold-and-kill” mechanism to achieve potent, cell-selective effects in disease-relevant tissues.

Read more about the deal here.

The Crowell deal team was led by Mark Cooper and included Melissa Paddock, Randa Adra, and Irina Goga.